中国普通人群及各类高危人群肝脏脂肪变性与纤维化患病率:覆盖570万成人的全国性研究
基于中国最大体检连锁数据库的横断面全国研究,纳入2017至2022年30个省份5757335名成人,用瞬时弹性成像评估脂肪变性与纤维化。脂肪变性、重度脂肪变性、进展性纤维化及肝硬化患病率分别为44.39%、10.57%、2.85%、0.87%。男性及肥胖、糖尿病、高血压、血脂异常、代谢综合征或转氨酶升高者各等级脂肪变性与纤维化患病率均显著更高。
要点
- 脂肪变性、重度脂肪变性、进展性纤维化、肝硬化患病率分别为44.39%、10.57%、2.85%、0.87%。
- 男性及肥胖、糖尿病、高血压、血脂异常、代谢综合征或转氨酶升高者脂肪变性与纤维化患病率显著更高。
- 脂肪肝、白蛋白或血小板计数降低及乙型肝炎病毒感染者的纤维化患病率显著高于健康对照。
核心结论
- 中国肝脏脂肪变性与纤维化疾病负担沉重,研究为普通人群筛查与风险分层路径提供依据。
- 作者认为脂肪肝与肝纤维化应纳入疾病管理项目,作为高危人群筛查与定期监测的目标,尤其是糖尿病患者。
研究设计与样本
- 横断面、基于人群的全国性研究,基于中国最大体检连锁数据库。
- 纳入2017至2022年在30个省份接受体检的成人,共5757335名参与者。
- 采用瞬时弹性成像评估并分级脂肪变性与纤维化。
- 在普通人群及具有人口学、心血管和慢性肝病危险因素的各亚组中估计总体与分层患病率。
- 采用混合效应回归模型检验与脂肪变性和纤维化独立相关的预测因素。
主要发现
- 5757335名参与者中,脂肪变性、重度脂肪变性、进展性纤维化及肝硬化患病率分别为44.39%、10.57%、2.85%、0.87%。
- 男性及肥胖、糖尿病、高血压、血脂异常、代谢综合征或丙氨酸氨基转移酶或天冬氨酸氨基转移酶升高者,各等级脂肪变性与纤维化患病率均显著更高。
- 脂肪肝、白蛋白或血小板计数降低及乙型肝炎病毒感染者纤维化患病率显著高于健康对照。
- 大多数心血管和慢性肝病危险因素是脂肪变性与纤维化的独立预测因素,但血脂异常对纤维化例外。
临床怎么用
- 作者认为脂肪肝与肝纤维化应纳入疾病管理项目,作为高危人群筛查与定期监测的目标,尤其是糖尿病患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: This study aimed to estimate the prevalence of liver steatosis and fibrosis in the general population and populations with potential risk factors in China, so as to inform policies for the screening and management of fatty liver disease and liver fibrosis in general and high-risk populations. METHODS: This cross-sectional, population-based, nationwide study was based on the database of the largest health check-up chain in China. Adults from 30 provinces who underwent a check-up between 2017 and 2022 were included. Steatosis and fibrosis were assessed and graded by transient elastography. Overall and stratified prevalence was estimated among the general population and various subpopulations with demographic, cardiovascular, and chronic liver disease risk factors. A mixed effect regression model was used to examine predictors independently associated with steatosis and fibrosis. RESULTS: In 5,757,335 participants, the prevalence of steatosis, severe steatosis, advanced fibrosis, and cirrhosis was 44.39%, 10.57%, 2.85%, and 0.87%, respectively. Participants who were male, with obesity, diabetes, hypertension, dyslipidemia, metabolic syndrome, or elevated alanine aminotransferase or aspartate aminotransferase had a significantly higher prevalence of all grades of steatosis and fibrosis, and those with fatty liver, decreased albumin or platelet count, and hepatitis B virus infection also had a significantly higher prevalence of fibrosis than their healthy counterparts. Most cardiovascular and chronic liver disease risk factors were independent predictors for steatosis and fibrosis, except for dyslipidemia for fibrosis. CONCLUSIONS: A substantial burden of liver steatosis and fibrosis was found in China. Our study provides evidence for shaping future pathways for screening and risk stratification of liver steatosis and fibrosis in the general population. The findings of this study highlight that fatty liver and liver fibrosis should be included in disease management programs as targets for screening and regular monitoring in high-risk populations, especially in those with diabetes.
引用
- Man S, Deng Y, Ma Y, et al. Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China. Gastroenterology. 2023. PMID: 37380136. doi:10.1053/j.gastro.2023.05.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。